Expression and methylation status of BTG2 , PPP1CA , and PEG3 genes in colon adenocarcinoma cell lines: promising treatment targets

• Published in: Gastroenterology and hepatology from bed to bench 2022-01, Vol.15 (4), p.395-405
• Main Authors: Erfani, Mehran, Zamani, Mozhdeh, Tamaddon, Gholamhossein, Hosseini, Seyed Vahid, Mokarram, Pooneh
• Format: Article
• Language: English
• Subjects: Original
• ISSN: 2008-2258; 2008-4234
• DOI: 10.22037/ghfbb.v15i4.2577

This study investigated the association between methylation status and expression levels of , , and genes in colon cancer. Aberrant DNA methylation is one of the most important epigenetic modifications in the development of cancer. Evidence indicates that hypermethylation of various tumor suppressor genes could be a potential mechanism of colon tumorigenesis. The expression levels of , , and genes were evaluated in HT-29/219, HCT116, SW48, SW742, SW480, and LS180 cell lines using quantitative Real-Time PCR. The methylation status of and was determined by methylation-specific PCR (MSP) method, and the methylation pattern of PEG3 was evaluated by bisulfite sequencing PCR (BSP). To investigate the effect of methylation on the expression of these genes, all colon cancer cell lines were treated by 5-Azacitidine (5-Aza) and/or Trichostatin A (TSA). The expression levels of , , and were highly heterogeneous and quantitatively correlated to their promoter methylation status in the studied colon cancer cell lines. Treatment by 5-Aza and/or TSA increased the expression of the above-named genes in colon cancer cell lines. Overall, it seems that , , and act as tumor suppressor genes in colon cancer, and methylation is a potential mechanism for their loss of expression. Therefore, these genes may be considered as suitable targets for demethylation approaches and, eventually, colon cancer treatment. Combined treatment by 5-Aza and TSA may be a promising therapeutic strategy for colon cancer treatment. Further studies may contribute to confirm these results.